stockrow
Friday 6 November 2026
Export FBIO’s income statement to Excel — free account
Fortress Biotech, Inc.
FBIO Healthcare Biotechnology
Fortress Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $63.3 million, up 9.69% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −116.0%
- Free cash flow
- −115.4%
- Total debt
- −35.7%
Quarter to June 2026, against a year earlier
1.85
0.01
+0.54%
Follow FBIO
Alert me
Fortress Biotech, Inc. (FBIO) P/E ratio
As of 6 November 2026, Fortress Biotech, Inc. (FBIO) trades at a P/E ratio of 0.6×. Over the past ten years it has ranged from 0.0× (March 2026) to 1.1× (July 2026); the current reading is higher than 95% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.9× | 29.19% |
| Mar 2026 | 0.7× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.1×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CNXU Conexeu Sciences Inc. compare | n/m |
| CGTX Cognition Therapeutics, Inc. compare | n/m |
| NORD Nordicus Partners Corporation compare | n/m |
| CRDF Cardiff Oncology, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| TENX Tenax Therapeutics, Inc. compare | n/m |
| MAIA MAIA Biotechnology, Inc. compare | n/m |
| FBIO Fortress Biotech, Inc. | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.4× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)